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P < .001). Prior chemotherapy, lymphoid malignancies,
longer interval fromdiagnosis toHCT, andpositiveCMVstatus
were also associated with LOS, with a trend towards signiﬁ-
cance (P ¼ .06 for all). In multivariable, logistic regression
analyses, poor PS (OR 1.31 per 10 point decrease,P ¼ .031),
unrelateddonor (OR3.14 P< .001), cord blood transplantation
(OR 2.42, P¼ .048), CMVpositivity of either donor or recipient
(OR 1.91, P¼ .018), and CD34+ cell dose (OR 1.35 per 1x106/kg
decrease, P < .001) were signiﬁcantly associated with pro-
longed LOS. 5-year non-relapse mortality (NRM) for pts
hospitalized 6 wks was signiﬁcantly worse than for pts
hospitalized<6 wks (60.2% vs. 31.8%, P< .001), as was overall
survival (OS) at 5 years, (16.6% vs. 42.8%, P< .001). Therewere
no differences in the incidence or degree of acute GVHD.
In conclusion, hospitalization 6 wks following HCT is
associated with signiﬁcantly worse NRM and OS. Poor PS,
CMV positivity, decreased CD34+ cell dose, and unrelated
and cord blood transplants have previously been identiﬁed
as factors predictive of poor outcome and are also factors that
contribute to prolonged LOS. Efforts should be made to
optimize modiﬁable factors such as cell dose in HCT pts,
especially those with other risk factors, such as having an
unrelated or cord blood donor.363
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Purpose: Late-onset hemorrhagic cystitis (LOHC) is
a common complication following allogeneic hematopoietic
stem cell transplantation (allo-HSCT), which was mainly
associated with BK virus and adenovirus (ADV). However,
there still some patients developed LOHC without infection
of BKV and ADV. Several retrospective studies showed that
CMV infection was associated with LOHC. So, we design this
prospective study to deﬁne the relationship between CMV
infection and LOHC.
Design and Methods: Fifty consecutive patients who
received allo-HSCT between October 2011 and December
2011 were prospectively investigated to screen BKV, ADV and
CMV in the urine and plasma using Real-time Polymerase
Chain Reaction (RT-PCR).Results: Twenty-one out of the 50 patients developed LOHC
with a cumulative incidence of 42%7.1%.The median time
from transplantation to onset of LOHC was 29 (range, 4-64)
days. There are 34 patients and 21 patients developed CMV
viremia and CMV viruria, respectively, within day 100. The
cumulative incidence of LOHC in patients with CMV viremia
was signiﬁcantly higher than those without CMV viremia
(58.8% vs. 6.3%, P ¼ .001) on day 100 after transplantation.
Patients with CMV viruria had a signiﬁcant higher cumula-
tive incidence of LOHC than those without CMV viruria
(60.7% vs. 18.2%, P ¼ .006). The cumulative incidence of CMV
viremia and CMV viruria in patients with LOHC (n¼21)
versus those without LOHC (n¼29) were 95.2% vs. 48.3% (P ¼
.001) and 80.9% vs. 34.5% (P ¼ .001), respectively. The
cumulative incidence of LOHC in patients whose plasma BKV
load increased more than or equal to 103-fold over baseline
was signiﬁcantly higher than those with plasma load
increase less than 103-fold (67.9%9.2%vs. 9.1%6.3%, P <
.001). The cumulative incidence of LOHC in patients whose
urine BKV load increased more than or equal to 104-fold over
baseline was signiﬁcantly higher than those with urine load
increase less than 104-fold (66.7% 10.3% vs. 19.2%7.9%, P ¼
.002). ADV was positive in 4 patients including one patient
with LOHC. Multivirariate analysis showed that CMV viremia
(HR¼10.496, 95% CI: 1.527-86.570, P ¼ .018) and plasma BKV
load increased more than or equal to 103-fold compared to
baseline level (HR¼10.669, 95% CI: 2.452-46.419, P ¼ .002)
were two independent risk factors for LOHC.
Conclusion: Our data suggest that CMV viremia is a risk
factor for LOHC following allo-HSCT.364
Investigation of ADAMTS13 and VWF in the Patients with
Thrombotic Complications Following Hematopoietic
Stem-Cell Transplantation (HSCT)
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Depei Wu. Department of Hematology, the First Afﬁliated
Hospital of Soochow University, China
Objective: Plasma ADAMTS13 may play a role in the patho-
genesis of hematopoietic stem-cell transplantation (HSCT)
related thrombosis by cleaving the prothrombotic ultralarge
VWF into less active VWF. This study was to investigate the
alterations of ADAMTS13 and VWF in HSCT recipients during
transplantation, and to evaluate their signiﬁcance in trans-
plantation-related thrombotic complications.
Methods: Plasma ADAMTS13 activity was detected by ﬂuo-
rescence resonance energy transfer substrate VWF73
(FRETS-VWF73) assay in 113 hematologic patients receiving
allogeneic-HSCT. Of all the patients recruited for his study, 8
patients were diagnosed to have the thrombotic disorders
and 49 patients were classiﬁed to have acute graft-versus-
host disease (aGVHD). The alterations of ADAMTS13 activity
and VWF level in the plasma of patients were analyzed
during transplantation, and the correlation between
ADAMTS13/VWF and transplantation-related thrombosis
was evaluated using the SAS program (version 9.3).
Results: The average plasma ADAMTS13 activity in 113 cases
following HSCT at each period were less than the healthy
controls (P< .01), while the VWF antigen level in each period
were higher than the controls (P < .05). Among all the
patients after pretreatment, 69 showed decreased plasma
ADAMTS13 activities (59.3%), including 9 patients with more
than 60% (8.0%) decrease, while the average plasma VWF
antigen level of this 69 patients was signiﬁcantly increased in
patients after pretreatment (P< .05). Considering thrombotic
complications, the data showed that 8 patients with
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activity (P < .01) and increased VWF antigen level after
pretreatment (P< .01) as comparedwith the non-thrombotic
patients; three out of 8 (37.5%) showed more than 60%
decrease in plasma ADAMTS13 activity. The level of
ADAMTS13 activity dropped in the 49 patients with aGVHD
as compared with healthy controls (P< .01), but therewas no
signiﬁcant difference between patients with and without
aGVHD. Twenty-ﬁve patients showed decreased plasma
ADAMTS13 activities only at the onset of aGVHD occurrence
(P < .01), in which two of them decreased more than 60%
(6%). Logistic regression analysis showed that the ADAMTS13
activity declined by more than 60% was the risk of throm-
bosis (P < .01).
Conclusions: We observed decreased plasma ADAMTS13
activity and increased plasma level of VWF antigen in
patients following HSCT after pretreatment, especially in the
patients with thrombotic complications. A decrease more
than 60% in plasma ADAMTS13 activity is the risk factor of
thrombotic complications. Therefore, the plasma ADAMTS13
activity could be an important parameter for the develop-
ment of vascular disorder, which has a potential role for the
early diagnosis of thrombotic complications.365
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Background: Hemostatic disorders are common and
potentially fatal complications in patients undergoing
hematopoietic stem-cell transplantation (HSCT). Limited
data exist on early diagnosis and prevention of these
complications. In this study, we retrospectively investigated
the outcome and risk factors associated with thrombotic and
bleeding complications in HSCT recipients.
Methods: From April 2004 to December 2011, 680 hemato-
logic patients receiving HSCT were enrolled in the study, and
their clinical manifestation and laboratory parameters were
analyzed for evaluating the outcome of hemostatic compli-
cations and related risk factors.
Results: Overal incidence of thrombotic complication, which
included 12 veno-occlusive diseases (VOD), 2 transplantation
related thrombotic microangiopathy (TA-TMA), 1 pulmonary
embolism (PE) and 1 deep vein thrombosis (DVT), was 2.4%
(16 cases). The overall mortality after thrombotic events was
68.8% (11 cases) in all HSCT recipients with thrombotic
complications. A total of 510 HSCT recipients (72.5%) devel-
oped bleeding events, including minor bleeding of 67.1%,
moderate bleeding of 28.4%, and severe bleeding of 3.9% of all
bleeding patients. By bleeding sites, 218 patients developed
hemorrhagic cystitis. Other organs of hemorrhage involved
skin or mucosa (46.5%), gastrointestinal tract (21.1%), vagina
(9.3%), and respiratory tract (1.3%). By risk factors analysis,
CD33 mAb use and preparative regimen containing total
body irradiation were signiﬁcantly associated with the
occurrence of thrombotic disorders (P < .05). Thrombocyto-
penia, grade 2-4 acute graft-versus-host disease (aGVHD),
allogeneic transplantation and infection were independent
risk factors for bleeding complication (P< .05). Polyomavirus
and grade 2-4 aGVHD were risk factors for hemorrhagic
cystitis (P < .05). The number of hemorrhagic sites was
signiﬁcantly correlated with bleeding severity (P < .05).Neither thrombotic nor bleeding disorders was correlated
with age, disease category, gender, transplantation types,
routine hemostatic parameters, or biochemical indicators.
Survival rate was correlated with the bleeding site and
intensity of bleeding disorders (P < .01). Respiratory and
gastrointestinal bleeding independently increased the
mortality of HSCT recipients, while overal cumulative
survival was decreased in patients with thrombotic compli-
cations. In addition, PAI-1 level in the HSCT recipients with
thrombotic complications were signiﬁcantly higher than
other complications (P < .01).
Conclusions: Our study suggested that HSCT patients with
thrombotic complications experienced high mortality while
the HSCT recipients with bleeding disorders had high
morbidity. Hence, early diagnosis and therapy of hemostatic
complications are crucial to improve the prognosis of HSCT
recipients.366
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Background:Many individual and treatment-related factors
impact post-allogeneic hematopoietic cell transplant (HCT)
immune reconstitution (IR). Our institution measures
lymphocyte subsets/activation status with 8-color ﬂow
cytometry panels at important milestones (e.g., development
of GVHD, day +365 evaluation), allowing for sensitive
monitoring of GVHD and post-HCT IR. We sought to identify
whether previously unrecognized patterns of CBC data and
lymphocyte subsets are associated with GVHD status.
Methods: 288 allogeneic HCT recipients have undergone
clinical IR testing at our institution since 2010. Included in
this analysis are 43 HCT patients who underwent testing for
IR with our updated antibody panel (CD3, CD4, CD8,
CD8beta, CD19, CD25, CD27, CD45, CD45RO, CD56, CD69, IgD,
and HLA-DR). Patients were classiﬁed according to clinical
status: no GVHD (9), active acute (3), resolved acute (6),
active chronic (18), and treated chronic GVHD (7). Differ-
ences in cell populations were determined by Kruskall-
Wallis tests. Multivariate pattern recognition techniques of
principal components/factor analysis (PCA/FA) and discrim-
inant analysis (DA) were used for exploratory predictive
modeling.
Results: Patients with active chronic GVHD had a signiﬁcant
increase in CD4-CD8- T cells (P ¼ .01) and trended towards
increased in NKT cells (P ¼ .06). PCA/FA revealed 3 factors
that account for 88% of the variability of the IR data (Factor
1¼CD4+, CD8+, and naïve T cells, Factor 2¼naïve and
switchedmemory B cells, and Factor 3¼absolute lymphocyte
counts [ALC] and platelet counts). By applying all variables
from the 3 factors in a DA model (Table), the ability to
discriminate between active vs. no GVHD approached
statistical signiﬁcance (P ¼ .06). Adding CD4-CD8- T cells and
NKT cells to the model did not allow for discrimination of
active vs. treated chronic GVHD. Lymphocyte activation (e.g.,
by HLA-DR or CD69 expression) could be identiﬁed in a few
patients who did not have overt GVHD or infections.
